Ureaplasma Urealyticum: Causes, Symptoms, and Treatment

Ureaplasma urealyticum is a tiny bacterium that lives in the urogenital tract of a large portion of healthy adults without ever causing trouble. It belongs to the Mollicutes class, organisms that lack a cell wall, and it gets its name from its unusual ability to break down urea as an energy source. Colonization rates in sexually active adults are high enough that the European STI Guidelines Editorial Board has cautioned against routine testing, noting that most carriers never develop disease.¹ Yet under certain conditions, this normally quiet resident can contribute to urethritis in men, complications in pregnancy, and measurable declines in semen quality.

A Bacterium That Runs on Urea

Most bacteria generate energy through familiar metabolic pathways involving sugars or amino acids. U. urealyticum is different. It relies almost entirely on urea, which is abundant in the urinary tract, to produce its cellular fuel. The organism contains an internal urease enzyme that splits urea into ammonia and carbon dioxide. That ammonia creates a chemical gradient across the bacterial membrane, and the cell harnesses that gradient to make about 95% of its ATP.² This peculiar energy strategy explains why the organism thrives in urine-bathed tissues and why it was originally called “T-strain mycoplasma,” the T standing for “tiny” because of the very small colonies it forms in culture.

There are actually two human Ureaplasma species, not one. What was once considered a single species was formally split in 2002 into U. urealyticum (10 serovars) and U. parvum (4 serovars).³ U. parvum is considerably more common in the general population, but U. urealyticum is more frequently linked to symptoms and disease when either species does cause problems. Older studies that predate the split often lump both species together under “Ureaplasma,” which muddies the picture when you try to figure out which organism is actually responsible for a given outcome.

How Common Is It, and Who Carries It

Colonization rates vary by population and study design, but the numbers are consistently high. In an Italian survey of women of childbearing age, U. parvum showed up in about 38% and U. urealyticum in roughly 9%.⁴ A Greek study of asymptomatic women found U. urealyticum in about 16% of cervical samples.⁵ A separate study comparing symptomatic and asymptomatic groups found U. urealyticum in 14% of people without any complaints.⁶

In men, a European position statement estimated that 40 to 80% of U. urealyticum detections in urethritis cases represent simple carriage rather than true infection.¹ The practical upshot is that a positive test result, by itself, does not mean the bacterium is causing your symptoms. This distinction between harmless carriage and actual infection is the central challenge with Ureaplasma and the reason clinical guidelines are cautious about testing and treatment.

How It Spreads

Sexual contact is the primary route of transmission between adults. The bacterium colonizes the mucosal surfaces of the urethra, vagina, and cervix, and is readily exchanged during unprotected intercourse. A large Chinese study identified several risk factors for infection: older age groups had progressively higher odds, women reporting multiple sexual partners had elevated risk, and lower levels of genital hygiene were associated with higher colonization. Interestingly, IUD use and other contraceptive methods were associated with slightly lower odds of infection.⁷

Mother-to-baby transmission also occurs, and the rate climbs with prematurity. One study found that the vertical transmission rate ranged from 38% in term infants to 95% in very low birth weight babies.⁸ This has important implications for neonatal health, discussed below.

Symptoms in Men

When U. urealyticum does cause symptoms in men, urethritis is the main presentation: burning during urination, urethral discharge, and irritation. The link between U. urealyticum and nongonococcal urethritis (NGU) has been debated for decades. A comprehensive review in Clinical Microbiology Reviews described the organism’s role in NGU and infertility as “highly controversial,” largely because healthy men carry it so often.⁹

Still, the evidence is stronger than “no association at all.” A Sydney-based study found that U. urealyticum was independently associated with NGU in men who had no other recognized urethral pathogen, with roughly twice the odds compared to uninfected men.¹⁰ Another study found that the association was especially pronounced in men with fewer lifetime sexual partners: those with fewer than five partners who tested positive for U. urealyticum had several times the odds of having NGU compared to negative controls.¹¹ One explanation is that men with many partners may have developed some degree of immunological tolerance to the organism, weakening the statistical signal. In men with less prior exposure, the same bacterium provokes a more detectable inflammatory response.

Symptoms in Women

The evidence for U. urealyticum as a direct cause of gynecological symptoms is surprisingly thin. A 2018 systematic review looked at its role in female infertility, genital discomfort, cervicitis, and pelvic inflammatory disease (PID). Five of six studies on infertility and five of six on genital discomfort found no association. The two studies that met criteria for cervicitis reached conflicting conclusions. No studies met the inclusion criteria for PID at all. The authors concluded that U. urealyticum has a “limited role as a pathogen in female infertility, cervicitis, PID, and genital discomfort.”¹²

That said, ureaplasma colonization does not exist in a vacuum. A Polish study found that women colonized with U. urealyticum had four times the odds of having bacterial vaginosis and significantly higher rates of co-infection with Mycoplasma hominis.¹³ Women with U. urealyticum colonization also showed a disrupted vaginal microbial community. In one study, control subjects without the organism tended to have a vaginal flora dominated by Lactobacillus iners, while colonized women showed no dominant Lactobacillus species at all.¹⁴ Whether the organism causes this disruption or simply thrives when lactobacilli decline is not fully settled, but the co-occurrence is worth knowing about.

Effects on Male Fertility

The evidence linking U. urealyticum to reduced semen quality is more robust than many people expect. A 2025 systematic review and meta-analysis pooling data across multiple studies found that men positive for U. urealyticum had lower ejaculate volume, lower sperm concentration, reduced total motility, lower normal morphology, and a higher seminal leukocyte count compared to uninfected men.¹⁵ The same analysis found higher levels of several inflammatory markers in the semen of positive men, along with more sperm DNA fragmentation and higher rates of sperm cell death.

A separate study specifically examining sperm morphology confirmed these findings, showing that semen cultures positive for U. urealyticum were associated with lower sperm concentrations, less forward motility, and poorer normal morphology.¹⁶ The proposed mechanism involves local inflammation: the organism triggers an immune response in the reproductive tract, and the resulting immune cells and inflammatory chemicals damage sperm directly. For couples having difficulty conceiving, testing for U. urealyticum in semen is reasonable and increasingly part of the fertility workup, even if the organism is not universally considered a fertility pathogen.

Pregnancy and Newborn Risks

Pregnancy is where the consequences of U. urealyticum colonization become most concerning. One study found that colonized pregnant women had significantly higher rates of amnionitis (35% vs 2%), premature rupture of membranes (35% vs 12%), and preterm delivery (41% vs 10%) compared to non-colonized controls.⁸ Another study found that women carrying both U. urealyticum and bacterial vaginosis had roughly three times the risk of delivering a low birth weight baby, while women with U. urealyticum alone still had about twice the risk.¹⁷

There is also evidence of a link between endocervical Ureaplasma colonization and tubal factor infertility. In a Brazilian study, women with positive endocervical bacterial cultures, including Ureaplasma, had about 2.2-fold higher odds of having tubal factor as the cause of their infertility.¹⁸ An older but influential study found that while U. urealyticum was present in cervical samples of about half of both fertile and infertile women, it was found in the endometrium significantly more often among infertile patients (26%) than among fertile controls (about 8%).¹⁹

For newborns, the risks concentrate among premature and very low birth weight infants. Ureaplasma colonization of the respiratory tract has been linked to bronchopulmonary dysplasia (BPD), a chronic lung disease of prematurity. Researchers have proposed that ureaplasma-driven inflammation, starting in utero and compounded by the mechanical ventilation and supplemental oxygen these babies often need, triggers a sustained immune response that disrupts normal lung development.²⁰ Pathology studies have found increased interstitial fibrosis in the lungs of ureaplasma-infected premature infants, with elevated inflammatory markers throughout the tissue.²¹ Epidemiological reviews also cite connections to intraventricular hemorrhage and necrotizing enterocolitis in these vulnerable babies.²²

How It Is Diagnosed

Ureaplasma is not part of routine STI screening panels in most countries. When testing is pursued, specimen types include urethral or vaginal swabs, urine, or semen, depending on the clinical scenario. Two broad methods are available: culture and molecular testing.

Traditional culture uses special media (Ureaplasma will not grow on standard bacteriology plates because it lacks a cell wall). Culture remains useful because it allows antibiotic susceptibility testing, but it is slow, taking days, and it cannot distinguish between U. urealyticum and U. parvum without additional steps. Molecular methods using PCR have become the more practical option. A multiplex PCR assay comparing favorably to culture showed sensitivity of 87% and specificity of 96% for detecting genital mycoplasmas, and it picked up infections that culture missed.²³ Real-time PCR assays have been developed that can distinguish U. parvum from U. urealyticum and even identify individual serovars, with detection limits as low as a few copies per reaction.²⁴ This species-level distinction matters clinically, since U. urealyticum is more consistently linked to disease than U. parvum.

Quantitative PCR is particularly valuable because bacterial load may matter more than mere presence. As noted earlier, a large share of U. urealyticum detections represent carriage, not infection. High organism loads are more likely to correlate with actual symptoms and inflammation, so a test that says “positive” without a count of organisms provides limited clinical guidance.

Treatment Options

When treatment is warranted, the mainstay antibiotics are tetracyclines and macrolides. U. urealyticum is naturally resistant to beta-lactam antibiotics like penicillin and cephalosporins because it has no cell wall for those drugs to target. The two agents used most often are doxycycline and azithromycin.

A study of Ureaplasma isolates from infertility and genital tract infection patients found that 91% were susceptible to doxycycline, making it the most reliable first-line choice. Susceptibility to azithromycin was somewhat lower at 71%.²⁵ A meta-analysis comparing azithromycin monotherapy to doxycycline found that the two were roughly equivalent in clearing the organism, with no meaningful difference in cure rates between them.²⁶ In practice, doxycycline (typically a 7- to 14-day course) is usually tried first because resistance rates are low, while azithromycin serves as an alternative, especially for patients who cannot tolerate tetracyclines or during pregnancy where doxycycline is generally avoided.

Fluoroquinolones like moxifloxacin are reserved for cases that do not respond to first-line drugs, partly because of resistance concerns and partly to preserve these broader-spectrum agents for situations that genuinely need them.

Rising Antibiotic Resistance

Resistance is a growing problem, particularly for fluoroquinolones. A Chinese study tracking resistance rates over several years found that while resistance to doxycycline, tetracycline, and josamycin stayed below 20%, fluoroquinolone resistance exceeded 50% and was climbing. Erythromycin resistance, by contrast, dropped from about 64% in 1999 to roughly 20% in subsequent years.²⁷

The genetic basis of this resistance is increasingly well characterized. A North American study examining isolates collected over more than a decade found that tetracycline resistance was driven by the tet(M) gene, present in all isolates with high-level resistance. Erythromycin resistance traced mainly to mutations in the 23S ribosomal RNA gene. For fluoroquinolones, mutations in the parC gene accounted for most resistance, with additional gyrA mutations conferring resistance to moxifloxacin as well.²⁸ French data confirmed the same pattern: the tet(M) gene in all tetracycline-resistant strains, parC or parE mutations in all levofloxacin-resistant strains, and additional gyrA mutations in those also resistant to moxifloxacin.²⁹

The practical takeaway is that doxycycline remains effective in most settings, but susceptibility testing is worth pursuing when initial treatment fails, especially in regions with high fluoroquinolone use.

The Testing and Treatment Controversy

One of the most heated debates in sexual health medicine is whether to test asymptomatic people for Ureaplasma at all. The European STI Guidelines Editorial Board put it bluntly: “At present, we have no evidence that we are doing more good than harm detecting and subsequently treating Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum colonizations/infections.”¹ Routine testing and treatment of asymptomatic men and women is not recommended under current guidelines.

The concern is not just about wasted antibiotics. Treating an organism that is behaving as a harmless commensal exposes patients to side effects, drives antibiotic resistance, and can create anxiety out of a lab finding that had no clinical meaning. On the other hand, in the context of unexplained urethritis, recurrent pregnancy loss, or a male fertility workup with abnormal semen parameters, targeted testing has clearer justification. The right approach depends on whether there is a clinical problem looking for an explanation, not whether a screening panel can detect the organism.

Extragenital Infections in Immunocompromised Patients

In people with healthy immune systems, U. urealyticum rarely causes trouble outside the urogenital tract. But in immunocompromised patients, particularly those with antibody deficiencies, the organism can cause surprisingly aggressive infections elsewhere in the body. Case reports have documented disseminated septic arthritis caused by U. urealyticum in a patient with low antibody levels following rituximab therapy.³⁰ Another case involved polyarthritis with spinal involvement in a patient being treated for acute leukemia, where the diagnosis was only made through advanced molecular testing of joint fluid.³¹

These cases are rare, but they highlight two practical points. First, Ureaplasma will not grow on standard culture plates, so clinicians have to think of it specifically and request the right test; otherwise the infection goes undetected. Second, antibody-mediated immunity appears to be the main defense that keeps ureaplasma confined to mucosal surfaces, which aligns with the high vertical transmission rates seen in premature infants whose immune systems are still immature.

How the Organism Provokes Inflammation

The immune response to Ureaplasma is not a one-size-fits-all reaction. Animal research has shown that asymptomatic urinary tract colonization triggers a mild, controlled immune response dominated by certain white blood cells, while colonization that leads to complications like kidney stone formation provokes a much more aggressive neutrophil-heavy response with extensive tissue changes.³²

In preterm infants, the immune interaction is particularly problematic. Lab studies using immune cells from premature, term, and adult donors showed that U. urealyticum stimulated release of pro-inflammatory signals while simultaneously blocking some of the counter-regulatory signals (like IL-6 and IL-10) that normally rein in inflammation. The result is a prolonged, unbalanced inflammatory state that may contribute to lung injury and make the infant more vulnerable to secondary infections.³³ More recent work has identified a specific Ureaplasma protein called GrpE that activates a signaling cascade in immune cells, triggering a metabolic shift toward glycolysis and ramping up the inflammatory output through a pathway involving TLR2, a sensor protein on the surface of macrophages.³⁴ Understanding these mechanisms is part of ongoing efforts to develop more targeted treatments, potentially ones that could calm the damaging inflammation without relying solely on antibiotics.